Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3613MR)

This product GTTS-WQ3613MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3613MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15836MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ2647MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ289MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ5692MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ9681MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ3438MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ7671MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ8121MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HGS-ETR2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW